Mark Geng
About Mark Geng
Mark Geng is a Senior Scientist in Biologics Product Development at Bristol-Myers Squibb in Boston, Massachusetts, with extensive experience in biologics drug substance manufacturing sciences and technology.
Senior Scientist at Bristol-Myers Squibb
Mark Geng holds the position of Senior Scientist in Biologics Product Development at Bristol-Myers Squibb, based in Boston, Massachusetts, United States. His role involves developing biologic therapies aimed at treating serious diseases. His work in biopharmaceutical research and development focuses on biologics, showcasing his expertise in this specialized area.
Previous Roles at Bristol-Myers Squibb
Before his current role, Mark Geng served as Scientist II in Biologics Drug Substance Manufacturing Sciences and Technology at Bristol-Myers Squibb from 2017 to 2018. During this period, he was based in Boston, Massachusetts, and contributed to various manufacturing sciences and technology projects for biologic drugs.
Experience at MilliporeSigma
Mark Geng has extensive experience from his time at MilliporeSigma, where he held multiple roles. As a GLP Study Director for viral clearance from 2016 to 2017 in Washington, D.C., he oversaw critical studies ensuring the safety and efficacy of biologic products. Prior to that, he was the Biologics Downstream Leader from 2015 to 2016, managing processes vital for the purification and production of biopharmaceuticals.
Leadership at Parabon Computation, Inc.
From 2014 to 2015, Mark Geng worked as the Development Group Leader for NIH Small Business Innovation Research projects at Parabon Computation, Inc. in Washington, D.C. His leadership role involved overseeing innovative research projects aimed at advancing biomedical technologies.
Academic Background and Research
Mark Geng earned his Ph.D. in Protein Engineering and DNA Nanotechnology from the University of Maryland, where he studied from 2008 to 2014. Additionally, he briefly studied at the Yale University School of Medicine in 2014. He also holds a Bachelor's degree in Science from Wuhan University, obtained between 2003 and 2007. His academic focus on protein engineering and DNA nanotechnology has greatly contributed to his expertise in biologics.